-

Agilent Introduces New Handheld Raw Material ID System for Pharmaceutical Manufacturers

Instrument verifies through both transparent and non-transparent packaging

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the newest instrument in its Raman technology portfolio. The new Agilent Vaya Raman raw material identity verification system is a handheld instrument that accelerates quality control testing in the pharmaceutical and biopharmaceutical industries.

Vaya verifies raw material identity through unopened transparent and non-transparent packaging, testing more containers for the same cost by reducing the need for sampling. Incoming goods can be tested quickly in the warehouse on receipt, reducing operator time and sample-handling booth usage. Testing through sealed containers also avoids handler exposure to high potency APIs and maintains the shelf life of sterile contents, helping to prevent unnecessary waste.

“Improving the speed and efficiency of raw material testing has a major impact on pharma and biopharma manufacturing,” said Paul Loeffen, Agilent vice president and general manager of the company’s Molecular Spectroscopy Division. “Testing requirements are trending toward higher volumes, even 100% of containers in many cases, and conventional techniques can be extremely resource-intensive. Vaya’s through-container capability bypasses the bottlenecks, offering our customers a significant cost- and resource-saving solution.”

Vaya is the first true through-barrier handheld Raman instrument, incorporating Agilent’s spatially offset Raman spectroscopy (SORS) technology for fast ID of incoming goods through opaque containers in a GMP ready package. Vaya combines SORS with conventional Raman spectroscopy for maximum compatibility with a wide range of packaging–from clear glass vials and plastic bags to opaque plastics and paper sacks.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

More News From Agilent Technologies Inc.

Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2026 after the stock market closes on Wednesday, May 27. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo...

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...
Back to Newsroom